Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Valneva Reports FY 2020 Results and Major Corporate Achievements
VALNEVAFebruary 25, 2021 GMT
Excellent progress on clinical programs
Unprecedented partnering deal signed with Pfizer for Lyme disease vaccine candidate VLA15, including $130 million upfront payment as part of over $300 million for upfront and milestone payments
Positive initial Phase 2 results
Acceleration of pediatric development announced
Acceleration of chikungunya vaccine candidate VLA1553 into Phase 3
Only Phase 3 chikungunya vaccine program to date worldwide
Potentially eligible for Priority Review Voucher (PRV)1 - for first company to receive Biologics License Application (BLA) approval
Two days after violence related to Somalia’s delayed elections, the country’s foreign ministry has accused “external forces” for contributing to the problems